Table 1.
Baseline characteristics of COVID-19 survivors, primary Raynaud's phenomenon patients and control subjects at the time of nailfold videocapillaroscopy.
| Controls (N = 30) |
Primary Raynaud's phenomenon (N = 31) |
Mild/moderate COVID-19 (N = 34) |
Severe COVID-19 (N = 27) |
||
|---|---|---|---|---|---|
| Sex | Males | 10 (33.3%) | 7 (22.6%) | 11 (32.4%) | 22 (81.5%) |
| Females | 20 (66.7%) | 24 (77.4%) | 23 (67.6%) | 5 (18.5%) | |
| Age (years) | 58.1 ± 13.36 59.0 (31.0–80.0) |
59.7 ± 14.60 58.0 (35.0–88.0) |
59.4 ± 14.13 59.5 (23.0–88.0) |
57.1 ± 11.96 61.0 (32.0–75.0) |
|
| BMI (kg/m2) | Normal | 27 (90.0%) | 27 (87.1%) | 31 (91.2%) | 20 (74.1%) |
| Obesity | 3 (10.0%) | 4 (12.9%) | 3 (8.8%) | 7 (25.9%) | |
| Smoking habit | No | 28 (93.3%) | 29 (93.5%) | 33 (97.1%) | 26 (96.3%) |
| Yes | 2 (6.7%) | 2 (6.5%) | 1 (2.9%) | 1 (3.7%) | |
| Primary Raynaud's phenomenon |
No | 30 (100.0%) | 0 (0.0%) | 34 (100.0%) | 27 (100.0%) |
| Yes | 0 (0.0%) | 31 (100.0%) | 0 (0.0%) | 0 (0.0%) | |
| Primary Raynaud's phenomenon duration (years) |
/ | 10.4 ± 8.60 10.0 (1.0–37.0) |
/ | / | |
| Presence of at least one comorbidity | No | 11 (36.7%) | 11 (35.5%) | 8 (23.5%) | 8 (29.6%) |
| Yes | 19 (63.3%) | 20 (64.5%) | 26 (76.5%) | 19 (70.4%) | |
| Concomitant drugs | No | 11 (36.7%) | 9 (29.0%) | 13 (38.2%) | 6 (22.2%) |
| Yes | 19 (63.3%) | 22 (71.0%) | 21 (61.8%) | 21 (77.8%) | |
Results are express as: mean with standard deviation and median with range (minimum-maximum), or with frequency and percentage, as appropriate. BMI: Body Mass Index (“Normal”: between 16 and 30 kg/m2; “Obesity”: more than 30 kg/m2).